U.S. General Merchandise and Department Stores Stock News

Resideo Technologies has nearly doubled investors' money over the past three years, and the current valuation checks suggest the stock still trades at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating room above the recent US$35.83 share price. Resideo Technologies has returned 98.4% over the past three years, which puts extra focus on whether that gain is fully backed by fundamentals. The planned spin off of the ADI Global Distribution business may support...

Voter support is tilting toward democratic socialist policies like universal healthcare, higher taxes on the wealthy, and more government-backed services, and that puts parts of the healthcare sector squarely under the spotlight. For investors, the bigger question is how potential future reforms and tougher oversight could affect margins, pricing power, and long term business models. This article examines the political catalysts behind this shift and then outlines 3 healthcare stocks that...

Assurant stock has delivered a strong 124.2% return over the past three years, yet the valuation picture is split, with the Excess Returns intrinsic value estimate pointing to meaningful upside while market multiples suggest the shares trade at a premium. Over three years, Assurant has returned 124.2%, which puts extra focus on whether today’s price still leaves room for attractive risk adjusted returns. Upcoming earnings, where analysts expect pressure on EPS, may influence views on the...

Earlier in July 2026, U.S. regulators expanded approval of Vertex’s gene-editing therapy Casgevy to children as young as 2 with sickle cell disease or transfusion-dependent thalassemia, while Canada’s pan-Canadian Pharmaceutical Alliance signed a Letter of Intent with Vertex to enable public reimbursement discussions for its cystic fibrosis therapy ALYFTREK. These moves deepen Vertex’s reach in severe genetic diseases by both widening the eligible patient pool for Casgevy and advancing payer...

S&P Global stock has delivered a 5 year return of 18.8%, yet its valuation checks currently lean expensive, which raises the question of how much of the story around new products and operating changes is already reflected in the US$450.84 share price. That 18.8% return over five years suggests S&P Global has rewarded patient shareholders, but not at a pace that clearly justifies paying any price for future growth. New offerings such as ETF Intelligence and a refreshed Market Intelligence...

Ameris Bancorp (ABCB) heads into its next earnings report on July 23 with expectations for higher year over year earnings and revenue, putting fresh attention on how the stock prices in those forecasts. See our latest analysis for Ameris Bancorp. The recent 7 day share price return of 2.10% and 30 day share price return of 7.32% suggest momentum has been building in Ameris Bancorp ahead of its earnings update. At the same time, the 1 year total shareholder return of 38.48% and 3 year total...

FMC (FMC) stock is in focus after the company submitted its first regulatory dossier for the new herbicide rimisoxafen to the U.S. Environmental Protection Agency, marking the compound’s initial global filing. See our latest analysis for FMC. Despite the positive headlines around rimisoxafen, FMC’s recent trading tells a different story, with the share price down 34.7% over 90 days and the 1 year total shareholder return declining 72.4%. This points to fading momentum as investors reassess...

Target Hospitality stock has delivered a very large 359.6% total return over the past five years, yet the current valuation checks lean expensive, with a low overall value score and market multiples that screen as overvalued. A 359.6% five year return means long term shareholders have already seen substantial gains, so fresh buyers are coming in after a strong run. Future contract wins and utilization levels can support earnings and cash flow, but any disappointment in occupancy or pricing...

Tradeweb Markets (TW) is back in focus after reporting June and second quarter 2026 operating metrics that show sharply higher trading activity, alongside a move to supply institutional bond pricing into the Pyth Network’s digital and onchain ecosystem. See our latest analysis for Tradeweb Markets. Despite the strong June and second quarter trading metrics, Tradeweb Markets’ recent share price return has been weak, with the stock down over the past quarter and year to date. However, the three...

Trump Media & Technology Group’s plan to charge up to US$100,000 per month for high speed API access to President Trump’s Truth Social posts is turning market information itself into a premium product. When a single message can jolt the S&P 500, oil prices, or individual stocks, the gap between traders who see that data first and everyone else can matter. This article looks at three stocks exposed to this new pay to see model, with one potentially positioned on the right side of the trend and...

Sticky inflation, a firm jobs market, and a Federal Reserve that signals it may keep policy tight or even tighten further all put a spotlight on companies tied to AI infrastructure and data centers. Capital spending linked to AI could both support earnings potential and add fresh inflation pressure, so stock selection matters. This article looks at how those macro forces intersect with AI related demand, and highlights three stocks with positive exposure from our AI Infrastructure and Data...

Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its current checks paint a picture of a stock that screens as expensive rather than a clear bargain. Over the past 3 years, Eton Pharmaceuticals has delivered a very large total return of about 13x. This puts extra focus on whether recent optimism has already been reflected in the share price. Recent momentum around a new FDA approved drug agreement can support expectations for future revenue...

Cleveland-Cliffs stock is coming off a difficult stretch, with the share price down 57.0% over the past 5 years, yet both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and conventional market multiples currently point to the shares trading below what the underlying cash flows may justify. The 57.0% share price decline over 5 years leaves existing holders with a steep loss, while raising the question of whether expectations have swung too far to the pessimistic...

CAVA Group stock has given investors a solid 41.1% gain over the past three years, yet the latest valuation checks and recent share price pullback raise questions about whether the current level still makes sense or now leans expensive. Over the past three years, CAVA Group has returned 41.1%. This puts the recent share price weakness into context as a pause after a stronger multi year run. The planned expansion of the restaurant base can support higher revenue expectations over time. The...

WaFd (WAFD) has put up a clean set of Q3 2026 numbers, with total revenue of about US$194.5 million and basic EPS of roughly US$0.85 feeding into trailing 12 month revenue of about US$761.1 million and EPS of around US$3.17. The company has seen revenue move from about US$721.1 million on a trailing basis in Q3 2025 to roughly US$761.1 million by Q3 2026, while trailing EPS shifted from about US$2.62 to US$3.17, setting the backdrop for investors weighing slower top line growth against firmer...

nLIGHT’s stock has delivered very strong gains over the past few years, yet the latest valuation checks, including an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples, both point to the shares trading at a premium to those fundamentals. Over the last 3 years, nLIGHT has returned about 376.6%, which puts extra focus on whether recent gains are already pricing in much of its future potential. The recent award of a Pentagon contract with funding...

Merit Medical Systems stock has delivered a modest 15.2% gain over the past five years, and today its valuation signals are split. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while earnings-based multiples suggest the shares trade at a premium. That tension leaves investors weighing a DCF view that screens the stock as undervalued against a market multiple read that looks less forgiving. Over five years, Merit Medical Systems has returned 15.2%, which...

Leadership transition at Napco Security Technologies Napco Security Technologies (NSSC) has announced a leadership transition that shifts founder Richard Soloway from Chief Executive Officer to Founder and Executive Chairman, while long-time executive Kevin Buchel steps into the Chief Executive Officer and President roles. For investors watching Napco Security Technologies stock, the move concentrates day-to-day operational responsibility with Buchel, who has more than 25 years of experience...

Happen (HAPN) is drawing investor interest after recent share price moves, with the stock down about 2% on the day and around 5% over the past week, despite modest gains over the past month. See our latest analysis for Happen. Set against a 1 year total shareholder return of 47.47% and a 3 year total shareholder return of 88.16%, Happen's recent 7 day share price decline of 5.50% suggests momentum has cooled in the short term, while longer term holders remain ahead. If Happen's swings have...

Public Service Enterprise Group stock sits at an interesting point where a 51.8% gain over the past five years meets a current valuation picture that looks roughly in line with an intrinsic value estimate from a Dividend Discount Model (DDM). At the same time, market multiples still lean toward the shares screening as undervalued. Over the past 5 years, Public Service Enterprise Group has returned 51.8%, which suggests long term holders have been rewarded even though the stock has been...

Rayonier (NYSE:RYN) has appointed Ryan Daniels as Senior Vice President, Wood Products. Daniels steps into the permanent role after serving as Interim SVP, Wood Products. He previously held operational roles at PotlatchDeltic before its recent merger with Rayonier. Rayonier, trading at about $21.8 per share, is in the middle of integrating its wood products operations following its merger with PotlatchDeltic. The appointment of Ryan Daniels formalizes leadership over one of the company’s...

After a strong three year gain of 107.1%, Hanover Insurance Group no longer looks obviously cheap, and the current checks point to a stock that is priced roughly in line with its fundamentals rather than at a clear bargain. Over the past 3 years, Hanover Insurance Group has returned 107.1%, which puts extra attention on whether recent share price strength is already baking in much of the good news. The recently announced CEO succession plan can support confidence in continuity and execution...

Catalyst Pharmaceuticals stock has delivered a very large 5 year return, yet the latest valuation checks suggest the current price looks roughly in line with what the broader fundamentals support rather than clearly cheap or clearly stretched. Over the past 5 years, Catalyst Pharmaceuticals has returned about 4.6x, which puts extra focus on whether the recent share price now simply reflects the progress already made. The agreed acquisition by Angelini Pharma can support confidence in the...

Brookdale Senior Living Inc. recently reported that for June 2026 its consolidated weighted average occupancy rose to 82.5%, with both month‑end and same‑community measures improving year over year and sequentially. Alongside this operational progress, Brookdale refinanced part of its 2027 debt, extended its revolving credit facility, and acquired the Brookdale Galleria community in Houston using cash and its expanded credit line. We’ll now examine how Brookdale’s improved occupancy and...